Regeneron Pharmaceuticals, Inc. (REGN) to Issue Quarterly Dividend of $0.88 on March 20th

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced a quarterly dividend on Monday, February 17th,RTT News reports. Shareholders of record on Thursday, February 20th will be given a dividend of 0.88 per share by the biopharmaceutical company on Thursday, March 20th. This represents a $3.52 annualized dividend and a yield of 0.52%. The ex-dividend date is Thursday, February 20th.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $673.60 on Tuesday. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The business’s 50 day moving average price is $706.92 and its 200-day moving average price is $894.87. Regeneron Pharmaceuticals has a 52 week low of $642.00 and a 52 week high of $1,211.20. The stock has a market cap of $74.02 billion, a P/E ratio of 17.60, a P/E/G ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the previous year, the firm posted $11.86 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals will post 36.67 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on REGN. Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada lowered their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Wells Fargo & Company lowered their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Sanford C. Bernstein lowered their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Finally, Oppenheimer lowered their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.